Abstract: The present invention relates to therapeutic compounds, novel RNA interference (RNAi) agents, that decrease expression of the Voltage-Gated Sodium Channel Alpha Subunit 10 (SCN10A) gene, which encodes a subunit of the Nav 1.8 or Nav 1.8 sodium channel. Such RNAi agents decrease levels of intact Nav 1.8 sodium channels and are useful in the treatment of diseases involving the regulation of SCN10A expression and function, such as chronic pain.
| # | Name | Date |
|---|---|---|
| 1 | 202517117867-STATEMENT OF UNDERTAKING (FORM 3) [27-11-2025(online)].pdf | 2025-11-27 |
| 3 | 202517117867-Sequence Listing in PDF [27-11-2025(online)].pdf | 2025-11-27 |
| 4 | 202517117867-REQUEST FOR EXAMINATION (FORM-18) [27-11-2025(online)].pdf | 2025-11-27 |
| 5 | 202517117867-POWER OF AUTHORITY [27-11-2025(online)].pdf | 2025-11-27 |
| 6 | 202517117867-FORM 18 [27-11-2025(online)].pdf | 2025-11-27 |
| 7 | 202517117867-FORM 1 [27-11-2025(online)].pdf | 2025-11-27 |
| 8 | 202517117867-DECLARATION OF INVENTORSHIP (FORM 5) [27-11-2025(online)].pdf | 2025-11-27 |
| 9 | 202517117867-COMPLETE SPECIFICATION [27-11-2025(online)].pdf | 2025-11-27 |
| 10 | 202517117867-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [27-11-2025(online)].pdf | 2025-11-27 |